Vanda Pharmaceuticals Inc. said it is looking to raise funds via an underwritten public offering.
Citigroup Inc., Jefferies Group LLC and Stifel Financial Corp. are acting as the joint book-running managers for the offering, which is not yet priced.
The Washington, D.C.-based biopharmaceutical company expects to use the proceeds for commercial and research and development activities, as well as for general corporate purposes.
